2003•Chinese Journal of New Drugs and Clinical RemediesRequires access

Mechanism and clinical efficacy of rosiglitazone in treating type 2 diabetes

Yao Zhu

Abstract

The basic cause of type 2 diabetes is the insulin resistance and the beta cells dysfunctional. Rosiglitazone can improve insulin sensitivity, protect the function of pancreatic B cells and steadily control the blood glucose. This article explains the mechanism and clinical efficacy of rosiglitazone in treating type 2 diabetes mellitus.

About this research paper

What this paper is about

Why it matters

A significance statement is not available in the OpenAlex record.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

Key concepts: Rosiglitazone, Medicine, Type 2 diabetes, Insulin resistance, Diabetes mellitus, Type 2 Diabetes Mellitus, Internal medicine, Insulin